Business · 27/01/2026Updated: 10/16/2026 · 1 min read
Determination of Regulatory Review Period for Purposes of Patent Extension; TRYVIO
Summary
The FDA has determined the regulatory review period for TRYVIO, a human drug product, and is publishing this notice as required by law. The review period is due to a patent extension application submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →